NASDAQ · SNYR

Synergy CHC Corp.

$0.17 +$0.00 (+1.97%) 1D After hours

Key Metrics

$2.49M
Market cap
P/E · TTM
$27.70M
Revenue · TTM
−$15.79M
Net income
EPS · TTM $-1.84
Dividend yield
Free cash flow
Beta · 1Y 0.97
EBITDA · TTM
Gross margin 65.4%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 23
    From its Jan 30 high, the share price fell 91%.

    Peak close $1.87 on Jan 30; trough close $0.17 on Jul 23. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -91%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Apr 2
    The stock moved -21.6% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 2
  • Apr 1
    The stock moved -20.9% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 1

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$2.49M
Enterprise value$27.22M
Shares outstanding14.9M
52-wk range$0.16 – $3.99
Avg volume · 20D700.3K
Net cash −$24.73M
Book value / share$-2.96
IndustryMedicinal Chemicals & Botanical Products
ExchangeNASDAQ
About Synergy CHC Corp.
IPO dateNov 7, 2013
Employees28

Synergy CHC Corp is a provider of consumer health care, beauty, and lifestyle products. It is engaged in the business of marketing and distributing consumer-branded products through various distribution channels in the health and wellness industry.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.09
P/FCF
EV/EBITDA
EV/Sales0.98
Graham №

Profitability

Gross 65.4%
Operating -56.6%
Net -57.0%
FCF
ROE / ROIC 75.1% · 2,323.9%

Financial Health

Current ratio0.93
Quick ratio0.43
Debt / equity-0.98
Debt / EBITDA
Net cash −$24.73M
Working capital−$503.86K

Cash Flow · TTM

Operating CF −$3.81M
Capex
Free cash flow
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-16.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings